

Appl. No. 10/672,683
Reply to Office Action of April 21, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-18. (canceled)

19. (currently amended) A method for enhancing the inhibitory activity of an anticancer drug in cervical carcinoma cells, hepatocellular carcinoma cells, or breast cancer cells, comprising administering to the cells abietic acid or ~~derivative thereof~~ dehydroabietic acid in combination with the anticancer drug.

20. (previously presented) The method of claim 19, wherein the cells are human.

21. (currently amended) The method of claim 19, wherein the abietic acid or ~~derivative thereof~~ dehydroabietic acid and anticancer drug are administered simultaneously.

22. (currently amended) The method of claim 19, wherein the abietic acid or ~~derivative thereof~~ dehydroabietic acid and anticancer drug are administered sequentially.

23. (previously presented) The method of claim 19, wherein the anticancer drug is taxol.

24. (previously presented) The method of claim 19, wherein the anticancer drug is mitomycin C.

25. (currently amended) A method for increasing the permeability of cervical carcinoma cells, hepatocellular carcinoma cells, or breast cancer cells, comprising contacting the cells with abietic acid or a ~~derivative thereof~~ dehydroabietic acid in combination with an anticancer drug.

26. (previously presented) The method of claim 25, wherein the cells are human.

Appl. No. 10/672,683

Reply to Office Action of April 21, 2005

27. (currently amended) The method of claim 25, wherein the cells swell and become round in morphology after exposure to abietic acid or a derivative thereof dehydroabietic acid.

28-29. (canceled)